Company Strategy

Our objective is to become a leading biopharmaceutical company by developing and commercializing a diverse portfolio of best-in-class biologic products for large proven markets.

The key elements of our strategy to achieve this objective are:

• Leverage the extensive biopharmaceutical experience of our management team and the power of the LEX System to source and develop high-value product candidates
• Continue to develop our current product candidates, Locteron, BLX-155 and BLX-301
• Position Locteron as the interferon of choice for the treatment of chronic hepatitis C
• Position BLX-155 to address multiple large-market indications involving blood clots
• Establish an effective commercial infrastructure as we progress toward regulatory approval
• Continue to strategically partner with leading pharmaceutical and biotechnology companies

Return to top